Skip to main content
. 2014 Jan 2;2014:126586. doi: 10.1155/2014/126586

Figure 1.

Figure 1

Cellular mechanisms of metformin and sorafenib effects against GBM CSCs. Metformin and sorafenib selectively target CSCs from which GBMs develop, acting on three key features: self-renewal, tumorigenicity, and differentiation ability. Fading arrows mean that metformin and sorafenib restrain specific CSC features, while the green arrow depicts an induction towards CSC differentiation mediated by metformin and sorafenib.